IO Biotech Named Among Fast Company's World's Most Innovative Companies of 2025

Core Insights - IO Biotech has been recognized as the 9th most innovative company in the biotechnology category by Fast Company for its innovative approach to immune-modulatory cancer vaccines [1][2][4] - The company is focused on developing off-the-shelf cancer vaccines that can be available at the time of patient diagnosis, aiming to change the oncology treatment paradigm [2][4] - IO Biotech's lead investigational cancer vaccine candidate, Cylembio®, is currently in a global Phase 3 clinical trial for advanced melanoma, with primary endpoint readout expected in Q3 2025 [4][6] Company Overview - IO Biotech is a clinical-stage biopharmaceutical company headquartered in Copenhagen, Denmark, with a US office in New York [6] - The company specializes in immune-modulatory therapeutic cancer vaccines based on its T-win® platform, which targets both tumor cells and immune-suppressive cells in the tumor microenvironment [6] - Cylembio® has received Breakthrough Therapy Designation from the US FDA for the treatment of advanced melanoma, based on positive Phase 1/2 data [6] Industry Recognition - Fast Company's list of the World's Most Innovative Companies includes 609 organizations across 58 sectors, highlighting companies that drive progress and innovation [3] - The recognition reflects IO Biotech's commitment to enhancing patient outcomes through innovative cancer treatment solutions [4][5]